A Jeff Aronin start­up qui­et­ly yanks its IPO as the biotech mar­ket ends year on a whim­per

Close to 6 months af­ter it ini­tial­ly post­ed its S-1 in what was still a thriv­ing biotech IPO mar­ket, Cas­tle Creek Bio­sciences has now yanked the of­fer­ing as new deals fade against the back­ground of a hard, year-end ap­praisal for drug stocks.

In its fil­ing with the SEC, Cas­tle Creek CEO Matthew Gantz mere­ly states that the biotech is no longer pur­su­ing an IPO. He had ini­tial­ly pen­ciled in a $100 mil­lion raise last sum­mer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER